Accelrys, Inc. (NASDAQ: ACCL) today reported financial results for the
fiscal quarter and year ended December 31, 2012, including a 16%
year-over-year increase in Non-GAAP revenue in the fourth quarter.

Non-GAAP revenue for the quarter ended December 31, 2012 increased $6.7
million to $47.5 million from $40.8 million for the same quarter of the
previous year, or an increase of 16%. Non-GAAP revenue for the year
ended December 31, 2012 increased $19.3 million to $174.3 million from
$155.0 million for the year ended December 31, 2011, or an increase of
12%.

Non-GAAP net income was $4.5 million, or $0.08 per diluted share, for
the quarter ended December 31, 2012 compared to non-GAAP net income of
$4.6 million, or $0.08 per diluted share, for the same quarter of the
previous year. Non-GAAP net income was $19.6 million, or $0.35 per
diluted share, for the year ended December 31, 2012 compared to non-GAAP
net income of $19.0 million, or $0.34 per diluted share, for the year
ended December 31, 2011.

GAAP revenue for the quarter ended December 31, 2012 increased $4.4
million to $44.2 million from $39.8 million for the same quarter of the
previous year, or an increase of 11%. GAAP revenue for the year ended
December 31, 2012 increased $18.2 million to $162.5 million from $144.3
million for the year ended December 31, 2011, or an increase of 13%.

GAAP net loss was $(8.2) million, or $(0.15) per diluted share, for the
quarter ended December 31, 2012 compared to GAAP net income of $14.2
million, or $0.25 per diluted share, for the same quarter of the
previous year. GAAP net loss was $(10.4) million, or $(0.19) per diluted
share, for the year ended December 31, 2012 compared to GAAP net income
of $1.8 million, or $0.03 per diluted share, for the same period of the
previous year.

“We are pleased with our performance in both 2012 and against the
three-year plan we developed for our business following our 2010 merger
with Symyx. We achieved both market momentum and acknowledgment of our
position as the leading provider of scientific innovation lifecycle
management software,” said Max Carnecchia, President and CEO.
“Performance in the fourth quarter of 2012 was strong as our revenues
grew 16% over the prior year. In addition, we completed and are
integrating three acquisitions key to our strategy of optimizing the
lab-to-market value chain. We remain enthusiastic about the market
opportunity in front of us and in our ability to continue to grow
orders, revenue and profits both organically and inorganically in 2013.”

Recent Business Highlights:

Completed three acquisitions that add important domain expertise and
technology capabilities that further our strategy to optimize the
innovation lifecycle from research through commercialization.

Aegis Analytical Corporation (Aegis), the leading provider of
process management informatics software, further expands the
footprint in downstream operation with solutions that help
aggregate, contextualize and analyze manufacturing, quality and
product development data.

Vialis AG, a leading systems integrator with deep experience
implementing and supporting paperless laboratory solutions,
further strengthening Accelrys' position in the laboratory
informatics software market.

Delivered new product releases in the core product lines and
significantly progressed the integration roadmap for the solutions
acquired into the portfolio, including:

New biology capabilities from screening through pre-clinical
development in the Accelrys Electronic Laboratory Notebook
(Enterprise Lab Management)

New Process Management and Compliance suite, a unified approach to
product development and process management which combines the
capabilities of the Accelrys ELN, Accelrys Lab Execution System
(LES), Accelrys Electronic Batch Records (EBR) and the Accelrys
Enterprise Platform (Enterprise Lab Management)

New integration between Accelrys Materials Studio and AEP,
enabling computational scientists to collaborate across the
enterprise; deepened biotherapeutics capabilities in Accelrys
Discovery Studio (Modeling and Simulation)

Non-GAAP results for the quarter and year ended December 31, 2012
exclude the impact of business combination activities associated with
the acquisitions of Aegis on October 23, 2012 and Contur Industry
Holding AB and Contur Software AB (collectively, “Contur”) and VelQuest
Corporation (“VelQuest”), both in 2011, and the merger with Symyx
Technologies, Inc. (“Symyx”) in 2010, and other nonrecurring items.

Non-GAAP revenue, non-GAAP operating income, and non-GAAP net income for
the quarter and year ended December 31, 2012 include fair value
adjustments to deferred revenue ($3.3 million and $11.8 million,
respectively). Non-GAAP operating income for such three and twelve-month
periods also excludes stock-based compensation expense ($2.5 million and
$8.1 million, respectively), business consolidation, transaction and
restructuring costs ($6.6 million and $7.8 million, respectively) and
purchased intangible asset amortization ($5.2 million and $17.8 million,
respectively), offset by an adjustment to include acquisition-related
cost of revenue related to VelQuest non-GAAP revenue recognized during
such periods ($0.8 million and $1.9 million, respectively). Non-GAAP net
income for the quarter and year ended December 31, 2012 also excludes
additional purchased intangible asset amortization ($0.4 million and
$1.7 million, respectively) offset by removing the impact of the
amortization of note receivable discount related to our promissory note
receivable from Intermolecular, Inc. (“Intermolecular”) ($0.3 million
and $0.9 million, respectively). In addition to the aforementioned
items, non-GAAP net income for the year ended December 31, 2012 includes
fair value adjustments to deferred royalty income of $0.6 million and
excludes $2.1 million in other non-operating income resulting from our
real estate related activities.

Calendar Year 2013 Outlook

For the year ending December 31, 2013, the Company expects non-GAAP
revenue to be between $185 and $190 million, and non-GAAP diluted
earnings per share to be between $0.36 and $0.39 per diluted share on
fully diluted weighted average shares outstanding of 56.6 million and
using an effective tax rate of 40%.

Non-GAAP Financial Measures:

This press release describes financial measures for revenue, operating
income, net income, net income per diluted share and free cash flow that
exclude deferred revenue fair value adjustments, acquisition-related
cost of revenue, business consolidation, transaction and restructuring
costs, stock-based compensation expense, purchased intangible asset
amortization, royalty income fair value adjustments, amortization of
note receivable discount, gain on sale of real estate, gain on sale of
equity investments, sale of intangible assets, other non-operating
expense and income tax adjustments. These financial measures are not
calculated in accordance with generally accepted accounting principles
(GAAP) and are not based on any comprehensive set of accounting rules or
principles.

Management believes these non-GAAP financial measures provide a useful
measure of the Company's operating results, a meaningful comparison with
historical results and with the results of other companies, and insight
into the Company's ongoing operating performance. Further, management
and the Board of Directors utilize these measures, in addition to GAAP
measures, when evaluating and comparing the Company's operating
performance against internal financial forecasts and budgets. These
non-GAAP financial measures should not be considered as a substitute
for, or superior to, measures of financial performance prepared in
accordance with GAAP. In addition, these non-GAAP financial measures may
be different from non-GAAP financial measures used by other companies.

For additional information on the items excluded by the Company from its
non-GAAP financial measures please refer to the Form 8-K regarding this
release that was furnished today to the Securities and Exchange
Commission.

The following table contains a reconciliation of the non-GAAP financial
measures to the most directly comparable GAAP financial measures (unaudited,
amounts in thousands, except per share amounts, including footnotes):

Three Months Ended

Year Ended

December 31,

December 31,

2012

2011

2012

2011

GAAP revenue

$

44,194

$

39,762

$

162,526

$

144,339

Deferred revenue fair value adjustment1

3,332

1,081

11,758

10,652

Non-GAAP revenue

$

47,526

$

40,843

$

174,284

$

154,991

GAAP operating loss

(11,203

)

(2,926

)

(19,054

)

(19,701

)

Deferred revenue fair value adjustment1

3,332

1,081

11,758

10,652

Acquisition-related cost of revenue2

(762

)

—

(1,921

)

—

Business consolidation, transaction and restructuring costs3

6,583

1,538

7,845

7,772

Stock-based compensation expense4

2,505

1,424

8,115

5,572

Purchased intangible asset amortization5

5,199

4,638

17,782

18,239

Non-GAAP operating income

$

5,654

$

5,755

$

24,525

$

22,534

Depreciation expense

872

923

3,325

3,800

Cash received for interest and royalty income

2,002

2,269

9,265

9,574

Cash (paid) for income taxes, net of refunds received

(198

)

(153

)

(2,690

)

1,182

Capital expenditures

(3,043

)

(934

)

(6,332

)

(3,908

)

Non-GAAP free cash flow

5,287

7,860

28,093

33,182

GAAP net income (loss)

$

(8,229

)

$

14,205

$

(10,402

)

$

1,765

Deferred revenue fair value adjustment1

3,332

1,081

11,758

10,652

Acquisition-related cost of revenue2

(762

)

—

(1,921

)

—

Business consolidation, transaction and restructuring costs 3

6,583

1,538

7,845

7,772

Stock-based compensation expense4

2,505

1,424

8,115

5,572

Purchased intangible asset amortization5

5,623

5,230

19,477

20,604

Royalty income fair value adjustment6

—

200

600

803

Amortization of note receivable discount7

(270

)

—

(932

)

—

Gain on sale of real estate8

—

—

(2,744

)

—

Gain on sale of equity method investment9

—

(18,970

)

—

(18,970

)

Sale of intangible assets10

—

4,303

—

4,303

Other non-operating expense11

—

—

670

—

Income tax12

(4,239

)

(4,456

)

(12,855

)

(13,454

)

Non-GAAP net income

$

4,543

$

4,555

$

19,611

$

19,047

GAAP diluted net income (loss) per share

$

(0.15

)

$

0.25

$

(0.19

)

$

0.03

Deferred revenue fair value adjustment1

0.06

0.02

0.21

0.19

Acquisition-related cost of revenue2

(0.01

)

—

(0.03

)

—

Business consolidation, transaction and restructuring costs3

0.12

0.03

0.14

0.14

Stock-based compensation expense4

0.04

0.03

0.14

0.10

Purchased intangible asset amortization5

0.10

0.09

0.34

0.37

Royalty income fair value adjustment6

—

—

0.01

0.01

Amortization of note receivable discount7

—

—

(0.02

)

—

Gain on sale of real estate8

—

—

(0.05

)

—

Gain on sale of equity method investment9

—

(0.34

)

—

(0.34

)

Sale of intangible assets10

—

0.08

—

0.08

Other non-operating expense11

—

—

0.01

—

Income tax12

(0.07

)

(0.08

)

(0.23

)

(0.24

)

Non-GAAP diluted net income per share13

$

0.08

$

0.08

$

0.35

$

0.34

Weighted average shares used to compute net income per share:

Basic

55,713

55,587

55,696

55,489

Diluted

56,848

55,933

56,563

56,037

1Deferred revenue fair value adjustment relates to our
acquisitions of Aegis, VelQuest and Contur and our merger with Symyx,
and adds back the impact of writing down the acquired historical
deferred revenue to fair value as required by purchase accounting
guidance.

2Acquisition-related cost of revenue relates to our
acquisition of VelQuest, and adds back the impact of writing down the
acquired deferred cost of revenue as required by purchase accounting
guidance.

3Business consolidation, transaction and restructuring costs
are included in the business consolidation, transaction and
restructuring costs line in our consolidated statements of operations
and consist of accounting, legal, litigation and other costs incurred in
connection with our acquisition activities, including our merger with
Symyx and acquisitions of Contur, VelQuest and Aegis, as well as
integration costs incurred in connection with such transactions,
including consultant and employee related costs incurred during
integration and transition periods. Also included are contingent
compensation costs relating to the Contur acquisition as well as lease
obligation exit costs, facility closure costs and severance and other
related costs incurred in connection with the various restructuring
activities commenced by the Company.

4Stock-based compensation expense is included in our
consolidated statements of operations as follows:

Three Months Ended

Year Ended

December 31,

December 31,

2012

2011

2012

2011

Cost of revenue

$

262

$

117

$

755

$

333

Product development

517

313

1,763

1,136

Sales and marketing

853

362

2,545

1,672

General and administrative

867

620

3,093

2,428

Business consolidation, transaction and restructuring costs

6

12

(41

)

3

Total stock-based compensation expense

$

2,505

$

1,424

$

8,115

$

5,572

5Purchased intangible asset amortization is included in our
consolidated statements of operations as follows:

Three Months Ended

Year Ended

December 31,

December 31,

2012

2011

2012

2011

Amortization of completed technology

$

2,580

$

2,135

$

8,843

$

8,393

Purchased intangible asset amortization

2,619

2,503

8,939

9,846

Royalty and other income, net

424

592

1,695

2,365

Total purchased intangible amortization expense

$

5,623

$

5,230

$

19,477

$

20,604

6Royalty income fair value adjustment relates to our merger
with Symyx, and adds back the impact of writing down deferred royalty
income to fair value as required by purchase accounting guidance.

7Amortization of note receivable discount adjusts the
amortization of the discount on our promissory note receivable from
Intermolecular in connection with the sale of intellectual property in
November 2011.

8Gain on sale of real estate relates to the sale of real
property, comprised of land and an office building located in Santa
Clara, California, which we sold in June 2012. This property was
acquired as a result of our merger with Symyx and was not utilized in
our ongoing operations.

9Gain on sale of equity investment reflects the gain
recognized upon the sale of our investment in Intermolecular in November
2011.

10Sale of intangible asset reflects the write off of our cost
basis in the intellectual property sold to Intermolecular in November
2011.

11Other non-operating expense relates to the write off in
June 2012 of certain assets in connection with exiting the lease of a
restructured facility net of other non-operating income.

12Income tax adjustments relate to adjusting our non-GAAP
operating results to reflect an effective tax rate of 40% that would be
applied if the Company was in a taxable income position and was not able
to utilize its net operating loss carryforwards. The income tax
adjustment also excludes any impact of a release of our valuation
allowance against deferred tax assets.

13Earnings per share amounts for the three months and year
ended December 31, 2012 do not add due to rounding.

Conference Call Details:

At 5:00 p.m. ET, February 26, 2013, Accelrys will conduct a conference
call to discuss its financial results. To participate, please dial (866)
309-0459 (+ (937) 999-3232 outside the United States) and enter the
access code, 88646167, approximately 15 minutes before the scheduled
start of the call. The conference call will also be accessible live on
the Investor Relations section of the Accelrys website at www.accelrys.com.

A replay of the conference call will be available online at www.accelrys.com
and via telephone by dialing (855) 859-2056 (+1 (404) 537-3406 outside
the United States) and entering access code, 88646167, beginning 8:00
p.m. ET on February 26, 2013, through 11:59 p.m. ET on April 26, 2013.

About Accelrys:

Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific
innovation lifecycle management software, supports industries and
organizations that rely on scientific innovation to differentiate
themselves. The industry-leading Accelrys Enterprise Platform provides a
broad and flexible scientific solution optimized to integrate the
diversity of science, experimental processes and information
requirements across the research, development, process scale-up and
early manufacturing phases of product development. By incorporating
capabilities in applications for modeling and simulation, enterprise lab
management, workflow and automation, and data management and
informatics, Accelrys enables scientific innovators to access, organize,
analyze and share data in unprecedented ways, ultimately enhancing
innovation, improving productivity and compliance, reducing costs and
speeding time from lab to market.

Accelrys solutions are used by more than 1,300 companies in the
pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer
packaged goods and industrial products industries. Headquartered in San
Diego, California, USA, Accelrys employs more than 200 full-time PhD
scientists. For more information about Accelrys, visit www.accelrys.com.

Forward-Looking Statements:

Statements contained in this press release relating to the Company's or
management's intentions, hopes, beliefs, expectations or predictions of
the future, including, but not limited to, statements relating to the
Company's expected non-GAAP revenue and diluted earnings per share for
the year ending December 31, 2013 and statements relating to the
Company's long-term prospects and execution of its strategic growth and
acquisition-related initiatives, are forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, risks that the Company
will not achieve its expected non-GAAP revenue or diluted earnings per
share for the year ending December 31, 2013 and/or that the Company will
not successfully execute its strategic growth and acquisition-related
initiatives, in each case due to, among other possibilities, an
inability to withstand negative conditions in the global economy or a
lack of demand for or market acceptance of the Company's products.
Additional risks and uncertainties faced by the Company are contained
from time to time in the Company's filings with the U.S. Securities and
Exchange Commission, including, but not limited to, the Company's Annual
Report on Form 10-K for the year ended December 31, 2011, quarterly
reports on Form 10-Q and current reports on Form 8-K. Collectively,
these risks and uncertainties could cause the Company's actual results
to differ materially from those projected in its forward-looking
statements, and the Company disclaims any intention or obligation to
revise any forward-looking statements whether as a result of new
information, future events or otherwise.

1Cash, cash equivalents, and marketable securities consist of
the following line items in our consolidated balance sheet: Cash and
cash equivalents; Restricted cash; Marketable securities; Marketable
securities, net of current portion; and Restricted cash, net of current
portion.

2Other assets, net, consists of the following line items in
our consolidated balance sheet: Prepaid expenses, deferred tax assets
and other current assets; Property and equipment, net; Goodwill;
Purchased intangible assets, net; and Other assets.

3Total deferred revenue consists of the following line items
in our consolidated balance sheet: Current portion of deferred revenue;
and Deferred revenue, net of current portion.

4Total deferred gain consists of the following line items in
our consolidated balance sheet: Current portion of deferred gain on sale
of intellectual property; and Deferred gain on sale of intellectual
property, net of current portion.

5Noncurrent liabilities, excluding deferred revenue and
deferred gain consists of the following line items in our consolidated
balance sheet: Accrued income tax; Accrued restructuring charges, net of
current portion and Lease-related liabilities, net of current portion.

As organizations abandon the waterfall method of software development for Agile, many are stuck in what Hasan Yasar terms Water-Scrum-Fall. That is, the organization has not effectively embraced Agile and DevOps principles and remains in silos with no links to business goals. Enter Dev...

In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, discussed the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is t...

The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process t...

Technology integration is complex and an evergreen business challenge for IT teams. Enterprises setup manual & point to point connections to exchange data from business partners. However, data disruptions emerge when the business IT systems expand and prevents organizations from sharin...

SYS-CON Events announced today that SourceForge has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SourceForge is the largest, most trusted destination for Op...

Most large organizations require dozens and sometimes hundreds of specialized software tools to manage the lifecycle of the physical products or software applications they create. It isn’t hard to imagine the monumental waste these organizations incur in attempting to manually coordina...